title: Integration of preclinical and clinical knowledge to predict intravenous PK in human: bilastine case study.
abstract: Modern pharmacometrics can integrate and leverage all prior proprietary and public knowledge. Such methods can be used to scale across species or comparators, perform clinical trial simulation across alternative designs, confirm hypothesis and potentially reduce development burden, time and costs. Crucial yet typically lacking in integration is the pre-clinical stage. Prediction of PK in man, using in vitro and in vivo studies in different animal species, is increasingly well theorized but could still find wider application in drug development. The aim of the present work was to explore methods for bridging pharmacokinetic knowledge from animal species (i.v. and p.o.) and man (p.o.) into i.v. in man using the antihistamine drug bilastine as example. A model, predictive of i.v. PK in man, was developed on data from two pre-clinical species (rat and dog) and p.o. in man bilastine trials performed earlier. In the knowledge application stage, two different approaches were used to predict human plasma concentration after i.v. of bilastine: allometry (several scaling methods) and a semi-physiological method. Both approaches led to successful predictions of key i.v. PK parameters of bilastine in man. The predictive i.v. PK model was validated using later data from a clinical study of i.v. bilastine. Introduction of such knowledge in development permits proper leveraging of all emergent knowledge as well as quantification-based exploration of PK scenario, e.g. in special populations (pediatrics, renal insufficiency, comedication). In addition, the methods permit reduction or elimination and certainly optimization of learning trials, particularly those concerning alternative off-label administration routes.
authors.affiliation: Drug Modeling & Consulting, Dynakin SL, PTB 801, Bilbao, Biscay, 48160, Spain, vozmediano@dynakin.com.
authors.forename: Valvanera
authors.initials: V
authors.lastname: Vozmediano
authors.forename: Ignacio
authors.initials: I
authors.lastname: Ortega
authors.forename: John C
authors.initials: JC
authors.lastname: Lukas
authors.forename: Ana
authors.initials: A
authors.lastname: Gonzalo
authors.forename: Monica
authors.initials: M
authors.lastname: Rodriguez
authors.forename: Maria Luisa
authors.initials: ML
authors.lastname: Lucero
mesh_terms: D061605:Administration, Intravenous; D000284:Administration, Oral; D000818:Animals; D001562:Benzimidazoles / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D004285:Dogs; D005260:Female; D006633:Histamine Antagonists / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D006801:Humans; D051188:Knowledge Bases; D008297:Male; D023421:Models, Animal; D008954:Models, Biological; D010880:Piperidines / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar; D015203:Reproducibility of Results; D013045:Species Specificity
chemical_list: D001562:Benzimidazoles; D006633:Histamine Antagonists; D010880:Piperidines; C445659:bilastine